Researchers used the 2010 to Q2 2022 M161Ortho PearlDiver Mariner Patient Claims Database to assess outcomes of single-level posterior lumbar fusions. Type 2 diabetic patients were grouped as either using insulin or not, and those using semaglutide were identified in those groups.
Of all the patients included, those who didn’t take insulin and those using semaglutide had significantly lower odds of minor adverse events and emergency room visits within 90 after surgery. Patients who used insulin and semaglutide had significantly lower odds of any type of adverse event postoperatively and emergency department visits.
The study “found consistent reductions in aggregated 90-day adverse events, but similar odds of hospital readmission for T2DM patients undergoing PLF taking semaglutide preoperatively. These encouraging findings of reduced postoperative complications suggest further prospective analysis, as the observed findings suggest clinical benefit to semaglutide being utilized by the studied patient population.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
